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Abstract—Prostate cancer is the most diagnosed form of cancer
in Canadian men, and is the third leading cause of cancer
death. Despite these statistics, prognosis is relatively good with
a sufficiently early diagnosis, making fast and reliable prostate
cancer detection crucial. As imaging-based prostate cancer
screening, such as magnetic resonance imaging (MRI), requires
an experienced medical professional to extensively review the
data and perform a diagnosis, radiomics-driven methods help
streamline the process and has the potential to significantly
improve diagnostic accuracy and efficiency, and thus improving
patient survival rates. These radiomics-driven methods currently
rely on hand-crafted sets of quantitative imaging-based features,
which are selected manually and can limit their ability to fully
characterize unique prostate cancer tumour phenotype. In this
study, we propose a novel discovery radiomics framework for gen-
erating custom radiomic sequences tailored for prostate cancer
detection. Discovery radiomics aims to uncover abstract imaging-
based features that capture highly unique tumour traits and
characteristics beyond what can be captured using predefined
feature models. In this paper, we discover new custom radiomic
sequencers for generating new prostate radiomic sequences using
multi-parametric MRI data. We evaluated the performance of the
discovered radiomic sequencer against a state-of-the-art hand-
crafted radiomic sequencer for computer-aided prostate cancer
detection with a feedforward neural network using real clinical
prostate multi-parametric MRI data. Results for the discovered
radiomic sequencer demonstrate good performance in prostate
cancer detection and clinical decision support relative to the
hand-crafted radiomic sequencer. The use of discovery radiomics
shows potential for more efficient and reliable automatic prostate
cancer detection.
Index Terms—Discovery radiomics, radiomic sequencing, au-
tomatic prostate cancer detection, multi-parametric magnetic
resonance imaging (MP-MRI), deep convolutional network, deep
features.
I. INTRODUCTION
Prostate cancer is the most diagnosed form of cancer (ex-
cluding non-melanoma skin cancers) in Canadian and Ameri-
can men. According to the Canadian Cancer Society [1], there
is an estimated 24,000 new cases and 4,100 deaths from it in
2015, making it the third most deadly cancer and accounting
for approximately 10% of cancer deaths in Canadian men.
Similarly in the United States, there is an estimated 220,800
new cases and 27,540 deaths from prostate cancer in 2015,
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making it the second most deadly cancer and accouting for
approximately 9% of cancer deaths in American men [2]. The
median patient survival time for metastatic prostate cancer
is between 12.2 to 21.7 months [3]. However, prognosis is
relatively good if the prostate cancer is detected early. As such,
fast and reliable prostate cancer screening methods are crucial
and can greatly impact patient survival rate, as the five-year
survival rate in Canada is 96% for patients diagnosed with
prostate cancer before the metastatic stage [4].
The current clinical model for initial prostate cancer screen-
ing employs a digital rectal exam (DRE) or a prostate-specific
antigen (PSA) test. Given a positive DRE or an elevated PSA,
a patient undergoes a follow-up transrectal ultrasound (TRUS)
guided multicore biopsy for risk stratification. The PSA in
particular has recently come under scrutiny, as recent studies
[5] [6] have demonstrated that the PSA test has a significant
risk of overdiagnosis with an estimated 50% of screened
men being diagnosed with prostate cancer. This oversensitivity
leads to expensive and painful needle biopsies and subsequent
overtreatment [5] [6] [7]. In addition, these prostate biopsies
cause discomfort, possible sexual dysfunction, and increased
hospital admission rates due to infectious complications while
having a chance of the biopsy needle missing the cancerous
tissue [8] [9]. The challenge diagnosticians currently face is
how to improve the detection of prostate cancer by reducing
the overdiagnosis due to conventional screening methods while
still maintaining a high sensitivity.
The use of magnetic resonance imaging (MRI) has recently
grown in popularity as a non-invasive imaging-based prostate
cancer detection method; however, a diagnosis through MRI
requires an experienced medical professional to extensively
review the data. Manual labelling of image data is time-
consuming, and can lead to diagnostic inconsistencies due to
variability between radiologists (inter-observer variability) and
the variability of a radiologist over multiple sittings (intra-
observer variability) [10] [11] [12]. To help raise the consis-
tency of radiologists, the European Society of Urogenital Ra-
diology (ESUR) introduced the Prostate Imaging - Reporting
And Diagnosis System (PI-RADS) as a common set of criteria
[13]. In addition, the use of multiple MRI modalities (multi-
parametric MRI) has been shown to improve prostate cancer
localization [14] via the extraction of unique information and
features from each modality. Despite PI-RADS and further
development to standardize diagnostic practices across multi-
parametric MRI [15], there is still a level of subjectiveness
in assessing MR images that can lead to inter-observer and
intra-observer variability.
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2Automatic computer-aided prostate cancer detection or ra-
diomics-driven methods for prostate cancer detection have
been developed to help streamline the diagnostic process
and increase diagnostic consistency. Radiomics refers to the
high-throughput extraction and analysis of large amounts of
quantitative features from medical imaging data to characterize
tumour phenotypes, allowing for a high-dimensional mineable
feature space that can be utilized for cancer detection and
prognosis [16]. The prognostic power of radiomics has been
previously shown in studies on lung and head-and-neck cancer
patients, indicating the potential of radiomic features for
personalized medicine and predicting patient outcomes [17]
[18].
Current radiomic-driven methods for prostate cancer detec-
tion typically employ a set of pre-defined, hand-crafted quan-
titative features extracted from multi-parametric MR images.
Lemaıˆtre et al. [19] recently published a comprehensive review
of state-of-art radiomics-driven methods for prostate cancer
detection and diagnosis. The hand-crafted feature models
used in these radiomics-driven methods typically included
some combination of the following: first-order and second-
order statistical features, Gabor filters, gradient-based features,
fractal-based features, pharmacokinetic features, and discrete
cosine transform (DCT) features.
Madabhushi et al. [20] assessed the utility of combining
multiple features for detecting prostate cancer in ex-vivo MRI
(i.e., prostates glands obtained via radical prostatectomy).
Three-dimensional texture feature sets were extracted from
MRIs that had been corrected for background inhomogeneity
and nonstandardness. The following feature sets were ex-
tracted and used to train an ensemble of classifiers: first-order
statistical features, second-order Haralick features, steerable
Gabor filters, and gradient-based features.
Tiwari et al. [21] proposed a method that combines struc-
tural and metabolic imaging data for prostate cancer detection
in multi-parametric MRI (including T2-weighting imaging and
magnetic resonance spectroscopy). Using similar features as
[20], Tiwari et al. detected cancerous regions within prostate
tissue using a random forest classifier.
Duda et al. [22] introduced a semi-automatic multi-image
texture analysis for the characterization of prostate tissue using
contrast-enhanced T1-weighted, T2-weighted, and diffusion-
weighted imaging. The method simultaneously analysed sev-
eral images (each acquired under different conditions) repre-
senting the same part of the organ. In addition to the features
used by [20], Duda et al. also extracted fractal-based and run
length features.
Litjens et al. [23] motivated their features with biology,
using features that represent pharmacokinetic behaviour, sym-
metry and appearance, and other anatomical aspects. Various
features were extracted from different MR images: second-
order statistical and Gabor features from T2-weighted images,
multi-scale blobness from apparent diffusion coefficient maps,
and curve fitting and pharmacokinetic features from contrast
enhanced images. These features were used for prostate gland
segmentation, generating a cancer likelihood map, and cancer-
ous region classification.
Ozer et al. [24] also proposed the use of pharmacokinetic
parameters derived from contrast-enhanced MRI, combining
it with T2-weighted and diffusion-weighted imaging. Using a
relevance vector machine (RVM) with a Bayesian framework,
Ozer et al. leveraged second-order statistical and (DCT) fea-
tures from the peripheral zone of multi-parametric prostate
MRI datasets to automatically segmented regions of cancer-
ous tissue, and evaluated the method against support vector
machines (SVM) with the same framework. Ozer et al. later
extended their work to select a threshold value for increased
segmentation performance, and further compared with a repre-
sentative unsupervised segmentation method (Markov random
field) [25].
Artan et al. [26] hand-crafted feature vectors using median-
filtered intensity values extracted from axial-oblique fast spin-
echo (FSE) T2-weighted, echo planar diffusion-weighted,
multi-echo FSE, and contrast-enhance MR images. Using
these features, Artan et al. developed a cost-sensitive SVM for
automated prostate cancer localization and showed improved
cancer localization accuracy over conventional SVMs. They
also combined a conditional random field with the cost-
sensitive framework that further improved prostate cancer
localization via the incorporation of spatial information.
Similar to [25], Liu et al. [27] introduced a method
for unsupervised prostate cancer segmentation using fuzzy
Markov random fields. They estimated the parameters of the
Markovian distribution of the measured data, and applied it
to parameter maps extracted from multi-parametric prostate
MRI (T2-weighted MRI, quantitative T2, diffusion-weighted
imaging, and contrast-enhanced MRI).
Vos et al. [28] developed a fully automatic computer-
aided detection method for prostate cancer using a supervised
classifier in a two-stage classification approach. As prostate
cancer can be discriminated from benign abnormalities due
to their heterogeneity, Vos et al. analysed lesion candidates
via the combination of a histogram analysis of T2-weighted
axial images, pharmacokinetic maps, contrast-enhanced T1-
weighted, and apparent diffusion coefficient maps with texture-
based features.
Khalvati et al. [29] proposed a multi-parametric MRI texture
feature model for radiomics-driven prostate cancer analysis.
The texture feature model, based on the one proposed by Peng
et al. [30], comprises of 19 low-level texture features extracted
from each MRI modality, including features extracted from
the gray-level co-occurrence matrix (GLCM). Khalvati et al.
[31] more recently published radiomics-driven models as an
extension of the previous texture feature model. An attempt at
designing comprehensive quantitative feature sequences, the
radiomics-driven models include additional MRI modalities,
additional low-level features, and feature selection.
While hand-crafted imaging-based feature models for
radiomics-driven methods for prostate cancer detection have
been shown to be highly effective, the generic nature of such
feature models for generating radiomic sequences can limit
their ability to fully characterize unique prostate cancer tumour
phenotype. Motivated by this, we introduce the concept of
discovery radiomics, where we forgo the notion of predefined
feature models by discovering customized, tailored radiomic
feature models directly from the wealth of medical imaging
3Fig. 1: Overview of the proposed discovery radiomics framework for prostate cancer detection. Multi-parametric MRI data
from past patients is used in the radiomic sequencer discovery process to discover a customized radiomic sequencer tailored for
prostate cancer. For a new patient case, the patient’s multi-parametric MRI data is fed into the discovered radiomic sequencer
to generate a custom, tailor-made radiomic sequence of abstract imaging-based features for tumor quantification and analysis.
data already available. Discovery radiomics has the potential
to find previously unexplored, abstract imaging-based features
that capture highly unique tumour traits and characteristics
beyond what can be captured using predefined feature models,
thus allowing for improved personalized medicine and risk
stratification through radiomic sequencing.
To realize the concept of discovery radiomics, we propose
a novel framework for discovering customized radiomic se-
quencers that can generate radiomic sequences of abstract
imaging-based features that are tailored for prostate cancer de-
tection using multi-parametric MRI. In this study, we introduce
very deep stochastic convolutional radiomic sequencers that
are discovered using multi-parametric MRI data captured from
past patient cases for generating custom radiomic sequences.
The paper is structured as follows. Patient data and the
underlying principles of the proposed discovery radiomics
framework for prostate cancer detection are described in
Section II. Experimental setup and comparative results are
shown in Section III. Lastly, conclusions are drawn and future
work is discussed in Section IV.
II. METHODS
The proposed discovery radiomics framework for prostate
cancer detection consists of the following steps (see Fig-
ure 1). First, standardized multi-parametric MRI data from
past patients along with pathology-verified radiologist tissue
annotations are fed into the radiomic sequencer discovery
process, where a customized radiomic sequencer is discov-
ered for generating a large number of abstract imaging-
based features that capture highly unique tumour traits and
characteristics pertaining to prostate cancer. Second, for a new
patient case, the discovered radiomic sequencer is then used
to generate a custom, tailor-made radiomic sequence from
the multi-parametric MRI data of the new patient case for
comprehensive, custom quantification of the prostate cancer
tumour phenotype. These discovered radiomic sequences can
then be used by a classifier to provide information for clinical
decision support for prostate cancer detection and diagnosis.
A. Patient Data Collection
A requirement of the proposed discovery radiomics frame-
work is the presence of standardized multi-parametric MRI
data from past patients. In this study, multi-parametric MRI
data of 20 patients was acquired using a Philips Achieva
3.0T machine at Sunnybrook Health Sciences Centre, Toronto,
Ontario, Canada. Institutional research ethics board approval
and patient informed consent for this study was obtained by
the Research Ethics Board of Sunnybrook Health Sciences
Centre. The patients’ ages ranged from 53 to 83. T2-weighted
(T2-w), diffusion-weighted imaging (DWI), and correlated
diffusion imaging (CDI) axial data was collected for each
patient to form the multi-parametric MRI dataset. Table I
summarizes the information regarding the acquired prostate
multi-parametric MRI data including displayed field of view
(DFOV), resolution, echo time (TE), and repetition time (TR).
The multi-parametric MRI dataset also includes annotation
information for isolating the prostate gland, and ground truth
data for the size and location of tumour candidates. As ground
truth, all images were reviewed and marked as healthy and
4Fig. 2: Architecture of the very deep stochastic convolutional radiomic sequencer introduced in this study. The radiomic
sequencer consists of 17 convolutional sequencing layers and two fully-connected sequencing layers. The weights of the
connections are determined stochastically based on a learned distribution.
TABLE I: Description of acquired prostate T2w, DWI, and
CDI imaging data comprising the multi-parametric MRI
dataset.
Modality DFOV (cm2) Resolution (mm3 TE (ms) TR (ms)
T2w 22× 22 0.49× 0.49× 3 110 4, 697
DWI 20× 20 1.56× 1.56× 3 61 6, 178
CDI 20× 20 1.56× 1.56× 3 61 6, 178
cancerous tissue by a radiologist with 18 and 13 years of
experience interpreting body and prostate MRI, respectively.
The multi-parametric MRI data and radiologist annotations
were verified as accurate using corresponding histopathology
data obtained through radical prostatectomy with Gleason
scores of seven or higher. The study used the following multi-
parametric MRI modalities: T2-weighted (T2w) imaging, ap-
parent diffusion coefficient (ADC) maps, computed high-b
diffusion-weighted imaging (CHB-DWI), and correlated dif-
fusion imaging (CDI). The modalities are summarized in the
following subsections.
1) T2-weighted Imaging (T2w): T2-weighted (T2w) imag-
ing is a MR imaging modality that characterizes the sensitivity
of tissue using the differences in transverse (spin-spin) relax-
ation time of the applied magnetic field. T2w imaging has
been shown to provide some localization information due to a
small reduction in signal for cancerous tissue in the prostate
gland [14].
2) Diffusion-Weighted Imaging (DWI): Diffusion-weighted
imaging (DWI) is an imaging modality in which the sensitivity
of the tissue to the Brownian motion water molecules is
measured through the application of lobe gradients (pairs of
opposing magnetic field gradient pulses) [32]. The diffusion-
weighted signal S is formulated as:
S = S0e
−bD (1)
where S0 is the signal intensity without diffusion weighting,
b is the gradient strength and pulse duration, and D is the
strength of the diffusion. The diffusion-weighted images are
typically generated using different b values, and can be used
to estimate apparent diffusion coefficient (ADC) maps via
least-squares or maximum likelihood methods [32]. Cancerous
tissue in ADC maps is usually presented with a darker intensity
relative to surrounding healthy tissue [33].
3) Computed High-b Diffusion Weighted Imaging (CHB-
DWI): Previous research has shown that high b-values in
DWI data (e.g., b-values greater than 1, 000s/mm2) allow for
increased delineation between healthy and cancerous tissue
[34] [35]. Due to hardware limitations, acquiring high b-
value images for prostate imaging is infeasible. CHB-DWI is
a computational model for reconstructing high b-value DWI
data using low b-value acquisitions [34] [36]. Our patient
data includes CHB-DWI images constructed at a b-value of
2, 000s/mm2 using a Bayesian model with the least-squares
estimation used to estimate our ADC maps.
4) Correlated Diffusion Imaging (CDI): Correlated Diffu-
sion Imaging (CDI) is a new diffusion MRI modality that
leverages the joint correlation in signal attenuation across
multiple gradient pulse strengths and timings to improve
delineation between cancerous and healthy tissue [37]. As
cancerous tissue generates higher intensities at high b-values,
better delineation can be achieved by adjusting the utilized
b-values for a given application. The overall characterization
of the water diffusion is better represented via the correlation
of signal attenuation across all b-values within a local sub-
volume, which is obtained via signal mixing [37]:
CDI(x) =
∫
...
∫ bn
b0
S0(x)...Sn(x)P (S0(x), ...Sn(x)|
V (x)× dS0(x)...dSn(x) (2)
where bi represents the utilized b-values, x is the spatial
location, S is the acquired signals, P represents the conditional
joint probability density function, and V (x) is the local sub-
volume centred at x.
B. Tumour Candidate Detection
As CDI [37] shows excellent delineation between cancerous
and healthy prostate tissue, tumour candidates were extracted
5from the dataset using a simple threshold on CDI data:
CDI(x)mask =
{
1 CDI(x) > CDImax2
0 otherwise
(3)
where CDI(x) refers to the CDI value at x, CDImax is the
max CDI value, and CDImask is the binary mask of tumour
candidates for a given MRI slice. A total of 80 cancerous
regions and 714 healthy regions were identified as tumour
candidates from the 20 different patients and used in this study.
C. Radiomic Sequencer Discovery
Given the standardized multi-parametric MRI data from
past patients and pathology-verified radiologist tissue anno-
tations, the radiomic sequencer discovery process discovers a
customized radiomic sequencer for generating a large number
of abstract imaging-based features that capture highly unique
tumour traits and characteristics pertaining to prostate cancer.
In this study, we introduce a novel very deep stochastic
convolutional radiomic sequencer, as shown in Figure 2, for
discovering custom-tailored radiomic sequences for prostate
cancer detection and diagnosis. Inspired by the very deep
convolutional network structure in [38], the proposed radiomic
sequencer consists of 17 convolutional sequencing layers and
two fully-connected sequencing layers of 1000 and 500 nodes,
respectively. An important challenge with conventional very
deep convolutional networks is that they have a large number
of parameters to learn, necessitating an extremely large dataset
for training. Due to the limited quantity of prostate cancer
patient cases that can be obtained, such networks cannot be
learned sufficiently and thus, it is difficult to use such networks
as radiomic sequencers. We address this important challenge
in two main ways in the proposed radiomic sequencer.
First and foremost, we forgo the notion of having the
weights of the connections between nodes be individual
parameters to learn, and instead have the weights of the
connections between nodes determined stochastically based
on a learned distribution. As such, the number of parameters
that must be learned is significantly reduced, making it well-
suited as a radiomic sequencer that can be discovered with a
reasonable amount of patient cases. Second, data augmentation
is performed via the rotation of each tumour candidate at 45◦
intervals (i.e., 0◦, 45◦, 90◦, 135◦, 180◦, 225◦, 270◦, 315◦).
While the proposed radiomic sequencer has significantly fewer
parameters to learn relative to conventional networks, the
current dataset is still insufficiently large to properly train the
radiomic sequencer. Therefore, data augmentation is used to
grow our existing dataset, resulting in 640 cancerous regions
and 5,712 healthy regions (as determined by corresponding
radiologist annotations and pathology data) that can now be
used as tumour candidates for training the proposed radiomic
sequencer. In this study, the proposed radiomic sequencer is
discovered via iterative scaled conjugate gradient optimization
using cross-entropy as the objective function.
In the proposed radiomic sequencer, each convolutional
sequencing layer (Figure 3) consists of stochastically realized
receptive fields, an absolute value rectification unit (AVReU)
to introduce non-saturating nonlinearity into the sequencer,
and a spatial overlapping median pooling layer. Detailed
descriptions of each part of the convolutional sequencing layer
is described in the following subsections.
Fig. 3: Each convolutional sequencing layer consists of
stochastically realized receptive fields, absolute value rectifi-
cation unit (AVReU), and spatial overlapping median pooling.
1) Stochastically Realized Receptive Fields: Unlike con-
ventional convolutional networks where the weights of recep-
tive field are trained via back propagation [39], the proposed
radiomic sequencer leverages stochastically realized receptive
fields to significantly reduce the number of parameters that
need to be learned. The connection weights encapsulated by
the receptive fields are abstracted into probability distributions,
and each receptive field represents the shared weights for all
localized nodal collections. In this study, each receptive field is
treated as a random field, with the connection weights in the
receptive field being spatially correlated subject to a spatial
correlation parameter ψ, which varies the level of spatial
correlation between connection weights within a receptive
field. As such, rather than learning individual connection
weights for the receptive fields, one now only needs to learn a
single parameter ψ. The proposed radiomic sequencer has 17
convolutional sequencing layers; the number of stochastically
realized receptive fields and receptive field size used in each
convolutional sequencing layer is specified in Table II.
TABLE II: Summary of number of stochastically realized
receptive fields and receptive field size at each convolutional
sequencing layer.
Convolutional
Sequencing Layer
Number of
Receptive Fields Receptive Field Size
1, 2 64 5× 5
3, 4 128 5× 5
5, 6, 7, 8 256 5× 5
9, 10, 11, 12, 13, 14,
15, 16 512 5× 5
17 2000 5× 5
2) Absolute Value Rectification Unit: Conventional con-
volutional networks typically model a nodes’s output f as
a function of its input x, such that f(x) = tanh(x) or
f(x) = (1+ e−x)−1. However, these saturating nonlinearities
train considerably slower than non-saturating nonlinearities
(generally referred to as Rectified Linear Units or ReLUs)
such as f(x) = max(0, x). Similar to Krizhevsky et al. [39],
we incorporate absolute value rectification units (AVReUs)
6(f(x) = |x|) to introduce non-saturating nonlinearity into the
proposed radiomic sequencer.
3) Spatial Pooling: Traditional local pooling layers in
convolutional neural networks encapsulate the outputs of
neighbouring nodes, and are typically done by pooling non-
overlapping neighbourhoods into a single value centred at the
location of the pooling neighbourhood [39]. Non-overlapping
spatial pooling is usually performed to reduce computational
complexity by indirectly decreasing the effective image size
after each pooling operation. Since with the proposed radiomic
sequencer the parameters are already significantly reduced, we
instead introduce a spatial non-overlapping median pooling
layer in each convolutional sequencing layer that preserves
the effective image size.
III. RESULTS
A. Experimental Setup
To assess the usefulness of the proposed discovery ra-
diomics framework for computer-aided prostate cancer de-
tection, the discovered radiomic sequencer (DRS) from the
proposed framework was compared against Peng et al.’s [30]
and Khalvati et al.’s [31] hand-crafted radiomic sequencers for
classifying tumour candidates as either healthy or cancerous
using a feedforward neural network classifier with a single
hidden layer of 100 nodes. While [30] and [31] evaluated
the hand-crafted radiomic sequencers for voxel-based clas-
sification via a linear discriminant analysis (LDA) classifier
and support vector machine (SVM), respectively, only the
hand-crafted radiomic sequencers themselves were included
in this study to assess the use of hand-crafted and discovered
radiomic sequencers. The performance of the classifier learned
based on each radiomic sequencer was evaluated using leave-
one-patient-out cross-validation using balanced training and
testing data (i.e., an equal number of healthy and cancerous
tumour candidates), and quantitatively assessed via sensitivity,
specificity, and accuracy metrics:
Sensitivity =
TP
P
Specificity =
TN
N
Accuracy =
TN + TP
N + P
where the performance of each method was quantified by
the metrics’ closeness to one. TP is the number of tumour
candidates identified as cancerous by both the classifier and
the radiologist’s tissue segmentation, TN is the number of
tumour candidates identified as healthy by both the classifier
and the radiologist’s segmentation, N is the number of tumour
candidates not in the radiologist segmented tissue (i.e., healthy
prostate tissue), and P is the number of tumour candidates in
the radiologist segmented tissue (i.e., cancerous tissue).
To further analyse the effectiveness of DRS relative to Peng
et al. [30] and Khalvati et al. [31], the Fisher criterion was
used to assess the separability of the generated imaging-based
features. The Fisher Criterion (FC) represents the separability
of the generated healthy and cancerous radiomic sequences.
The FC scores for the radiomic sequences generated for
healthy (h) and cancerous (c) candidate regions were computed
via the following:
FC =
(µh − µc)2
σh + σc
(4)
where µh and µc represent the mean values of the healthy
and cancerous radiomic sequences, respectively, and σh and
σc represent their respective standard deviations. A higher FC
score corresponds to a higher degree of separability between
the healthy and cancerous radiomic sequences, indicating the
better delineation between healthy and cancerous regions using
the generated radiomic sequences.
B. Results
The discovered radiomic sequencer (DRS) was evaluated
against two state-of-the-art hand-crafted radiomic sequencers
proposed by Peng et al. [30] and Khalvati et al. [31] for
classifying tumour candidates as either healthy or cancerous
using a feedforward neural network classifier with a single
hidden layer of 100 nodes. Sensitivity, specificity, and accuracy
were calculated via leave-one-patient-out cross-validation with
balanced training and testing datasets (as the majority of
the tumour candidates were healthy) to prevent the accuracy
metric from being strongly skewed by the specificity rate.
Table III shows the performance metrics for classification
using the hand-crafted radiomic sequencers [30] [31] and the
discovered radiomic sequencer.
TABLE III: Comparison of hand-crafted radiomic sequencers
[30] [31] with discovered radiomic sequencer (DRS) for
tumour candidate classification.
Sensitivity Specificity Accuracy
Peng et al. [30] 0.1824 0.9005 0.5821
Khalvati et al. [31] 0.3568 0.9231 0.6730
DRS 0.6400 0.8203 0.7365
As shown in Table III, Khalvati et al. [31] performed better
than Peng et al. [30] in terms of all performance metrics,
and produced the highest specificity at 92.31%. While [31]
has a high specificity, it is worth noting that the hand-crafted
radiomic sequencer also has the lowest sensitivity (i.e., pro-
portion of correctly identified cancerous tumour candidates)
at 35.68%, missing almost two thirds of the cancerous candi-
dates. This indicates that the hand-crafted radiomic sequencer
generates radiomic sequences that better represent tumour
candidates consisting of healthy tissue than tumour candidates
consisting of cancerous tissue.
Table III also shows that the discovered radiomic sequencer
produced the highest sensitivity at 64.00% and accuracy at
73.65%. In addition, the discovered radiomic sequencer has
noticeably more consistent performance across the metrics rel-
ative to both hand-crafted radiomic sequencers [30] [31], with
specificity at 82.03%. This suggests that the custom radiomic
sequences generated from the discovered radiomic sequencer
are better able to represent both healthy and cancerous prostate
tissue in a more balanced fashion, as opposed to favouring
healthy tissue.
7Statistical significance for each of the performance metrics
was performed via a paired two-sided null hypothesis test (as
shown in Table IV). The improvements in sensitivity using
the discovered radiomic sequencer is statistically significant
compared to both [30] and [31], with the improvements in
accuracy using the discovered radiomic sequencer statistically
significant compared to [30]. In addition, a separability anal-
ysis was performed using the Fisher Criterion; the results of
the separability analysis are shown in Table V.
TABLE IV: Paired two-sided null hypothesis test results
for statistical significance between hand-crafted radiomic se-
quencers [30] [31] and discovered radiomic sequencer (DRS).
Sensitivity Specificity Accuracy
p-value against [30] 0.0029 0.0165 0.0133
p-value against [31] 0.0277 0.0056 0.2396
Table V shows that DRS obtained the highest FC score
relative to Peng et al. [30] and Khalvati et al. [31]. This
indicates that the discovered radiomic sequences produced by
DRS has the best separability between healthy and cancerous
radiomic sequences. These results demonstrate the potential of
the proposed radiomics discovery framework for building cus-
tom radiomic sequencers that can generate radiomic sequences
tailored for prostate cancer characterization and detection.
TABLE V: Comparison of hand-crafted radiomic sequencers
[30] [31] with discovered radiomic sequencer (DRS) with
respect to separability of extracted features.
Fisher Criterion
Peng et al. [30] 0.0188
Khalvati et al. [31] 0.0144
DRS 0.0712
IV. CONCLUSION
In this study, a novel discovery radiomics framework for
prostate cancer detection using multi-parametric MRI data was
presented. Unlike conventional radiomics-driven methods that
use a set of hand-crafted radiomic features, the discovered
radiomic sequencer can generate radiomic sequences that are
specifically tailored for quantifying and differentiating healthy
and cancerous prostate tissue.
The performance of the discovered radiomic sequencer was
compared against two state-of-the-art hand-crafted radiomic
sequencers [30] [31] via leave-one-patient-out cross-validation
for the task of tumour candidate classification using a feed-
forward neural network. While [31] produced the highest
specificity (92.31%) and outperformed [30] with respect to
all metrics, the Khalvati et al.’s hand-crafted radiomic se-
quencer also produced the second lowest sensitivity (35.68%),
indicating that almost two thirds of cancerous candidates are
undetected. The discovered radiomic sequencer based on the
proposed discovery radiomics framework, however, produced
the highest sensitivity (64.00%) and accuracy (73.65%), and
has noticeably more consistent performance across the metrics
relative to [30] and [31], with specificity at 82.48%.
Future work includes the use of additional MRI modalities
(such as dual-stage correlated diffusion imaging [40]) to allow
the proposed framework to discover radiomic sequencers that
can produce more distinctive radiomic sequences for prostate
cancer, and the investigation of transfer learning [41] (e.g., the
application of a radiomic sequencer trained using non-prostate
imaging data to prostate cancer data). In addition, further
analysis of discovered sequences will be conducted to better
understand the prostate cancer phenotype. The application of
radiomic sequences can be extended to cancer grading and
staging, enabling a non-invasive method for assessing the
severity and behaviour of prostate cancer. As such, radiomic
sequencing can lead to better patient care and survival rates
through more reliable risk stratification.
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